ProCE Banner Activity

Expert Answers to Questions Regarding the Optimal Treatment of CLL

Clinical Thought

In this commentary, experts answer questions about the optimal treatment of chronic lymphocytic leukemia (CLL) asked at a live symposium at ASH 2024. 

Released: January 22, 2025

Expiration: January 21, 2026

Share

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, BeiGene, and Lilly.

AstraZeneca

BeiGene

Lilly

Partners

Clinical Care Options, LLC

ProCE Banner

Faculty Disclosure

Primary Author

Danielle M. Brander, MD

Associate Professor of Medicine
Division of Hematologic Malignancies & Cellular Therapy
Department of Medicine, Duke University
Duke Cancer Institute
Durham, North Carolina

Danielle M. Brander, MD: consultant/advisor: AbbVie, BeiGene, Bristol Myers Squibb, Pharmacyclics; researcher (paid to institution): AbbVie, ArQule/Merck, AstraZeneca/Acerta, BeiGene, Bristol Myers Squibb, Carna Biosciences, Catapult, DTRM, Genentech, NeWave, Nurix, Pharmacyclics, TG Therapeutics; other financial or material support: AbbVie, Pharmacyclics.

Brian Hill, MD, PhD

Director, Lymphoid Malignancies Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

Brian Hill, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Genentech.

Sameer A. Parikh, MBBS

Associate Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Sameer A. Parikh, MBBS: researcher (paid to institution): AstraZeneca, Genentech, Janssen, Merck; consultant/advisor/speaker (paid to institution): AbbVie, Amgen, AstraZeneca, BeiGene, Genentech, Janssen, Kite, Merck, MingSight, Novalgen Limited, Pharmacyclics, TG Therapeutics.